AstraZeneca Pharma Intrinsic Value
AstraZeneca Pharma (ASTRAZEN) median intrinsic value is ₹3080.00 from 9 valuation models (range ₹2594–₹7028), vs current price ₹8648.00 — -64.4% downside (Trading Above Calculated Value), margin of safety -100.0%. Browse ASTRAZEN cash flow statement for revenue, profit, balance sheet and cash flow data.
ASTRAZEN Valuation Methods Summary — DCF, Graham Number & P/E
AstraZeneca Pharma intrinsic value across 9 models vs current price ₹8648.00 — upside/downside and value range per method. Also explore AstraZeneca Pharma share price performance to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2594.40 | ₹2075.52 - ₹3113.28 | -70.0% | EPS: ₹46.30, Sector P/E: 22x |
| Book Value Method | asset | ₹3080.00 | ₹2772.00 - ₹3388.00 | -64.4% | Book Value/Share: ₹1540.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹7028.00 | ₹6325.20 - ₹7730.80 | -18.7% | Revenue/Share: ₹3514.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹5900.00 | ₹5310.00 - ₹6490.00 | -31.8% | EBITDA: ₹295.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3459.20 | ₹2767.36 - ₹4151.04 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2594.40 | ₹2334.96 - ₹2853.84 | -70.0% | EPS Growth: 5.6%, Fair P/E: 4.4x |
| Growth Adjusted P/E | growth | ₹2594.40 | ₹2334.96 - ₹2853.84 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹4324.00 | ₹3891.60 - ₹4756.40 | -50.0% | ROE: 15.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹2594.40 | ₹2334.96 - ₹2853.84 | -70.0% | EPS: ₹46.30, BVPS: ₹1540.00 |
ASTRAZEN Intrinsic Value vs Market Price — All Valuation Models
AstraZeneca Pharma fair value range ₹2594–₹7028 vs current market price ₹8648.00 across 9 valuation models. For current market price and key ratios, visit AstraZeneca Pharma share price screener.
ASTRAZEN Intrinsic Value Analysis — Undervalued or Overvalued?
AstraZeneca Pharma median intrinsic value ₹3080.00, current price ₹8648.00 — Trading Above Calculated Value by 64.4%, margin of safety -100.0%.
What is the intrinsic value of ASTRAZEN?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of AstraZeneca Pharma (ASTRAZEN) is ₹3080.00 (median value). With the current market price of ₹8648.00, this represents a -64.4% variance from our estimated fair value.
The valuation range spans from ₹2594.40 to ₹7028.00, indicating ₹2594.40 - ₹7028.00.
Is ASTRAZEN undervalued or overvalued?
Based on our multi-method analysis, AstraZeneca Pharma (ASTRAZEN) appears to be trading above calculated value by approximately 64.4%.
ASTRAZEN Financial Health — Key Ratios vs Industry Benchmarks
AstraZeneca Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 29.82 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.16x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ASTRAZEN Cash Flow Quality — Operating & Free Cash Flow
AstraZeneca Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹65 Cr | ₹65 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹28 Cr | ₹28 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹58 Cr | ₹58 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹101 Cr | ₹101 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹105 Cr | ₹105 Cr | Positive Free Cash Flow | 8/10 |